©2025 Stanford Medicine
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Recruiting
I'm InterestedTrial ID: NCT06465810
Purpose
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Official Title
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
Stanford Investigator(s)
Kevin M. Alexander, MD, FACC, FHFSA
Assistant Professor of Medicine (Cardiovascular Medicine)
Eligibility
Inclusion Criteria:
* Patient willing and able to provide written informed consent to participate in the study
* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
* Aged ≥18 years at the time of signing the informed consent
* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
Exclusion Criteria:
* Concurrent participation in any interventional trial for ATTR amyloidosis
* Involvement in the planning and/or conduct of the current study
* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers
Intervention(s):
drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
AstraZeneca Clinical Study Information Center
1-877-240-9479